Stool decay-accelerating factor as a marker for monitoring the disease activity during leukocyte apheresis therapy in patients with refractory ulcerative colitis

Hiroyuki Kohno, Motowo Mizuno, Junichirou Nasu, Chiho Makidono, Sakiko Hiraoka, Tomoki Inaba, Kazuhide Yamamoto, Hiroyuki Okada, Teizo Fujita, Yasushi Shiratori

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background and Aims: We have shown previously that concentrations of stool decay-accelerating factor (DAF; CD55), a complement regulatory protein, in patients with ulcerative colitis (UC) are increased in relation to the severity of the colonic mucosal inflammation. In the present study, we evaluated the usefulness of stool DAF as a marker for monitoring disease activity in patients with steroid-resistant active UC being treated with leukocyte apheresis performed with a centrifugal cell separator. Methods: Twenty-one patients with active and steroid-resistant UC were treated with leukocyte apheresis once a week for 4 weeks, and stool DAF concentrations were determined weekly by immunoassay. Results: After treatment, 11 (52%) of the 21 UC patients went into remission. Stool DAF concentrations decreased promptly and steadily in the responsive group. The difference reached statistical significance as soon as after the second apheresis session (P <0.003), compared with values before the therapy and corresponding values in the non-responsive group (P = 0.024). The reduction in stool DAF concentrations after the second apheresis session was significantly greater in the responsive group (median 90%, range 22-90%) than in the non-responsive group (median -13%, range -307-94%) (P = 0.008). Hematological tests, that is, white blood cell (WBC) count and C-reactive protein, declined significantly during the apheresis therapy, but not in relation to therapeutic response. Conclusion: Stool DAF concentration is a useful marker in the clinical response of UC patients to treatment with leukocyte apheresis.

Original languageEnglish
Pages (from-to)73-78
Number of pages6
JournalJournal of Gastroenterology and Hepatology (Australia)
Volume20
Issue number1
DOIs
Publication statusPublished - 2005

Fingerprint

CD55 Antigens
Blood Component Removal
Ulcerative Colitis
Leukocytes
Therapeutics
Steroids
Hematologic Tests
Leukocyte Count
Immunoassay
C-Reactive Protein
Complement System Proteins
Biomarkers
Inflammation

Keywords

  • CD55
  • Decay-accelerating-factor
  • Leukocyte apheresis
  • Ulcerative colitis

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology

Cite this

Stool decay-accelerating factor as a marker for monitoring the disease activity during leukocyte apheresis therapy in patients with refractory ulcerative colitis. / Kohno, Hiroyuki; Mizuno, Motowo; Nasu, Junichirou; Makidono, Chiho; Hiraoka, Sakiko; Inaba, Tomoki; Yamamoto, Kazuhide; Okada, Hiroyuki; Fujita, Teizo; Shiratori, Yasushi.

In: Journal of Gastroenterology and Hepatology (Australia), Vol. 20, No. 1, 2005, p. 73-78.

Research output: Contribution to journalArticle

Kohno, Hiroyuki ; Mizuno, Motowo ; Nasu, Junichirou ; Makidono, Chiho ; Hiraoka, Sakiko ; Inaba, Tomoki ; Yamamoto, Kazuhide ; Okada, Hiroyuki ; Fujita, Teizo ; Shiratori, Yasushi. / Stool decay-accelerating factor as a marker for monitoring the disease activity during leukocyte apheresis therapy in patients with refractory ulcerative colitis. In: Journal of Gastroenterology and Hepatology (Australia). 2005 ; Vol. 20, No. 1. pp. 73-78.
@article{fe6dc263a60d457b96b73c5cb9fbc2d7,
title = "Stool decay-accelerating factor as a marker for monitoring the disease activity during leukocyte apheresis therapy in patients with refractory ulcerative colitis",
abstract = "Background and Aims: We have shown previously that concentrations of stool decay-accelerating factor (DAF; CD55), a complement regulatory protein, in patients with ulcerative colitis (UC) are increased in relation to the severity of the colonic mucosal inflammation. In the present study, we evaluated the usefulness of stool DAF as a marker for monitoring disease activity in patients with steroid-resistant active UC being treated with leukocyte apheresis performed with a centrifugal cell separator. Methods: Twenty-one patients with active and steroid-resistant UC were treated with leukocyte apheresis once a week for 4 weeks, and stool DAF concentrations were determined weekly by immunoassay. Results: After treatment, 11 (52{\%}) of the 21 UC patients went into remission. Stool DAF concentrations decreased promptly and steadily in the responsive group. The difference reached statistical significance as soon as after the second apheresis session (P <0.003), compared with values before the therapy and corresponding values in the non-responsive group (P = 0.024). The reduction in stool DAF concentrations after the second apheresis session was significantly greater in the responsive group (median 90{\%}, range 22-90{\%}) than in the non-responsive group (median -13{\%}, range -307-94{\%}) (P = 0.008). Hematological tests, that is, white blood cell (WBC) count and C-reactive protein, declined significantly during the apheresis therapy, but not in relation to therapeutic response. Conclusion: Stool DAF concentration is a useful marker in the clinical response of UC patients to treatment with leukocyte apheresis.",
keywords = "CD55, Decay-accelerating-factor, Leukocyte apheresis, Ulcerative colitis",
author = "Hiroyuki Kohno and Motowo Mizuno and Junichirou Nasu and Chiho Makidono and Sakiko Hiraoka and Tomoki Inaba and Kazuhide Yamamoto and Hiroyuki Okada and Teizo Fujita and Yasushi Shiratori",
year = "2005",
doi = "10.1111/j.1440-1746.2004.03545.x",
language = "English",
volume = "20",
pages = "73--78",
journal = "Journal of Gastroenterology and Hepatology (Australia)",
issn = "0815-9319",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Stool decay-accelerating factor as a marker for monitoring the disease activity during leukocyte apheresis therapy in patients with refractory ulcerative colitis

AU - Kohno, Hiroyuki

AU - Mizuno, Motowo

AU - Nasu, Junichirou

AU - Makidono, Chiho

AU - Hiraoka, Sakiko

AU - Inaba, Tomoki

AU - Yamamoto, Kazuhide

AU - Okada, Hiroyuki

AU - Fujita, Teizo

AU - Shiratori, Yasushi

PY - 2005

Y1 - 2005

N2 - Background and Aims: We have shown previously that concentrations of stool decay-accelerating factor (DAF; CD55), a complement regulatory protein, in patients with ulcerative colitis (UC) are increased in relation to the severity of the colonic mucosal inflammation. In the present study, we evaluated the usefulness of stool DAF as a marker for monitoring disease activity in patients with steroid-resistant active UC being treated with leukocyte apheresis performed with a centrifugal cell separator. Methods: Twenty-one patients with active and steroid-resistant UC were treated with leukocyte apheresis once a week for 4 weeks, and stool DAF concentrations were determined weekly by immunoassay. Results: After treatment, 11 (52%) of the 21 UC patients went into remission. Stool DAF concentrations decreased promptly and steadily in the responsive group. The difference reached statistical significance as soon as after the second apheresis session (P <0.003), compared with values before the therapy and corresponding values in the non-responsive group (P = 0.024). The reduction in stool DAF concentrations after the second apheresis session was significantly greater in the responsive group (median 90%, range 22-90%) than in the non-responsive group (median -13%, range -307-94%) (P = 0.008). Hematological tests, that is, white blood cell (WBC) count and C-reactive protein, declined significantly during the apheresis therapy, but not in relation to therapeutic response. Conclusion: Stool DAF concentration is a useful marker in the clinical response of UC patients to treatment with leukocyte apheresis.

AB - Background and Aims: We have shown previously that concentrations of stool decay-accelerating factor (DAF; CD55), a complement regulatory protein, in patients with ulcerative colitis (UC) are increased in relation to the severity of the colonic mucosal inflammation. In the present study, we evaluated the usefulness of stool DAF as a marker for monitoring disease activity in patients with steroid-resistant active UC being treated with leukocyte apheresis performed with a centrifugal cell separator. Methods: Twenty-one patients with active and steroid-resistant UC were treated with leukocyte apheresis once a week for 4 weeks, and stool DAF concentrations were determined weekly by immunoassay. Results: After treatment, 11 (52%) of the 21 UC patients went into remission. Stool DAF concentrations decreased promptly and steadily in the responsive group. The difference reached statistical significance as soon as after the second apheresis session (P <0.003), compared with values before the therapy and corresponding values in the non-responsive group (P = 0.024). The reduction in stool DAF concentrations after the second apheresis session was significantly greater in the responsive group (median 90%, range 22-90%) than in the non-responsive group (median -13%, range -307-94%) (P = 0.008). Hematological tests, that is, white blood cell (WBC) count and C-reactive protein, declined significantly during the apheresis therapy, but not in relation to therapeutic response. Conclusion: Stool DAF concentration is a useful marker in the clinical response of UC patients to treatment with leukocyte apheresis.

KW - CD55

KW - Decay-accelerating-factor

KW - Leukocyte apheresis

KW - Ulcerative colitis

UR - http://www.scopus.com/inward/record.url?scp=19944433620&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19944433620&partnerID=8YFLogxK

U2 - 10.1111/j.1440-1746.2004.03545.x

DO - 10.1111/j.1440-1746.2004.03545.x

M3 - Article

C2 - 15610450

AN - SCOPUS:19944433620

VL - 20

SP - 73

EP - 78

JO - Journal of Gastroenterology and Hepatology (Australia)

JF - Journal of Gastroenterology and Hepatology (Australia)

SN - 0815-9319

IS - 1

ER -